Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-540-69441-0_36
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Rare manifestations of Russell’s viper (Daboia russelii) envenoming in Sri Lanka

  2021cited by this paper
• Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate

  2007cited by this paper
• Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

  2007cited by this paper
• Successful Liver‐Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H

  2007cited by this paper
• TTP and ADAMTS13: When Is Testing Appropriate?

  2007cited by this paper
• The interactive Factor H–atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models

  2007cited by this paper
• Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

  2007cited by this paper
• Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.

  2007cited by this paper
• A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome

  2007cited by this paper
• Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura

  2007cited by this paper
• A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2.

  2006cited by this paper
• Favorable Long‐Term Outcome after Liver‐Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation

  2006cited by this paper
• Thrombotic Thrombocytopenic Purpura-Then and Now

  2006cited by this paper
• In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura

  2006cited by this paper
• Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

  2006cited by this paper
• Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement.

  2005cited by this paper
• Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.

  2005cited by this paper
• Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

  2005cited by this paper
• Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.

  2005cited by this paper
• Relative Nephroprotection During Escherichia coli O157:H7 Infections: Association With Intravenous Volume Expansion

  2005cited by this paper
• Plenary Papers (356 articles)

  2005cited by this paper
• Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology.

  2004cited by this paper
• Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome

  2004cited by this paper
• The human complement factor H: functional roles, genetic variations and disease associations.

  2004cited by this paper
• The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice.

  2004cited by this paper
• Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome

  2004cited by this paper
• Refinement of a therapeutic Shiga toxin-binding probiotic for human trials.

  2004cited by this paper
• Mutations in CD46, a complement regulatory protein, predispose to atypical HUS.

  2004cited by this paper
• Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome

  2004cited by this paper
• The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome

  2003cited by this paper
• Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial.

  2003cited by this paper
• Familial haemolytic uraemic syndrome and an MCP mutation.

  2003cited by this paper
• Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.

  2003cited by this paper
• Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries

  2003cited by this paper
• The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children

  2003cited by this paper
• Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome

  2003cited by this paper
• Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection.

  2003cited by this paper
• Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands.

  2003cited by this paper
• Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

  2003cited by this paper
• Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections1

  2003cited by this paper
• Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.

  2002cited by this paper
• Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis.

  2002cited by this paper
• Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation

  2002cited by this paper
• von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

  2002cited by this paper
• Successful treatment of factor H-related haemolytic uraemic syndrome.

  2002cited by this paper
• Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy.

  2002cited by this paper
• Complement factor H and the haemolytic uraemic syndrome.

  2001cited by this paper
• Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.

  2001cited by this paper
• Intervention with Shiga toxin (Stx) antibody after infection by Stx-producing Escherichia coli.

  2001cited by this paper
• Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

  2001cited by this paper
• Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

  2001cited by this paper
• Familial hemolytic uremic syndrome associated with complement factor H deficiency.

  2001cited by this paper
• A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans

  2000cited by this paper
• The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

  2000cited by this paper
• Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura

  2000cited by this paper
• How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

  2000cited by this paper
• Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak.

  1999cited by this paper
• Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura

  1999cited by this paper
• von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

  1998cited by this paper
• Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.

  1998cited by this paper
• Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

  1998cited by this paper
• Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

  1996cited by this paper
• The pathophysiology and management of thrombotic thrombocytopenic purpura

  1996cited by this paper
• Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

  1994cited by this paper
• Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease.

  1993cited by this paper
• Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

  1991cited by this paper
• Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

  1991cited by this paper
• Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen

  1989cited by this paper
• Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial.

  1988cited by this paper
• A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home.

  1987cited by this paper
• Thrombotic microangiopathy in pregnancy and the postpartum period.

  1987cited by this paper
• Congenital defect in intracellular cobalamin metabolism resulting in homocysteinuria and methylmalonic aciduria. I. Case report and histopathology.

  1979cited by this paper

• Detection of Listeria monocytogenes, Escherichia coli and Salmonella species in Ready-to-eat Salad by Rapid Microbiological Detection Methods (Redox potential measurement + Real-time PCR)

  2018cites this paper
• Diagnosis and Management of Atypical Hemolytic Uremic Syndrome In Children: Single Centre Experience

  2014cites this paper
• Anesthetic management of cor pulmonale posted for fracture neck femur : Role of regional anesthesia

  2014cites this paper
• Transplant glomerulopathy and post-transplant de novo thrombotic microangiopathy: common features and pathologic mechanisms Glomerulopatia do transplante e microangiopatia trombótica de novo pós transplante: morfologia e mecanismos patológicos

  2014cites this paper
• Pathology of thrombotic microangiopathy

  2014cites this paper
• Unilateral hypertrophied right kidney and contralateral atrophy of left kidney: In a setting of malignant hypertension - A case report

  2013cites this paper
• Case records of the Massachusetts General Hospital. Case 30-2011. A 62-year-old woman with renal failure.

  2011cites this paper
• Patient with rheumatoid arthritis and acute renal failure: a case report and review of literature.

  2011influential citation